First Fully Percutaneous EVAR Approval From FDA

In short

Aortic graft specialist Endologix, Inc., has seen the U.S. FDA PMA supplement approved for its 21Fr profile and smaller EVAR systems.  This means a broadened indication for the company’s totally percutaneous endovascular aneurysm repair (PEVAR).


Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders with a specific focus on endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA).

Endologix’s EVAR platforms include the Powerlink® with IntuiTrak® System and the AFX™ Endovascular AAA System. This new approval means they are the first and only commercially available endografts to achieve the “totally percutaneous” indication, a procedure facilitated using Abbott’s  Perclose ProGlide® Suture-Mediated Closure System.

The Company expects to begin training physicians in the U.S. on the PEVAR procedure in the second quarter 2013.

The new approval is based upon the outcomes of the first prospective, multicenter, randomized clinical trial (The PEVAR Trial). Endologix says  the FDA approval provides the first clinical validation of PEVAR in a multicenter setting using the Company’s fully integrated, sheath-based EVAR systems that already had the industry’s only contralateral standard percutaneous (9Fr) indication.

The trial results, presented at recent medical meetings are pretty compelling. They found significant benefits following PEVAR compared to surgical vascular access EVAR. PEVAR procedures were completed in 34 minutes less time, required eight times fewer concomitant iliac/femoral artery procedures or repairs, and resulted in achievement of femoral artery hemostasis in 57% less time. Other positive trends favoring PEVAR included reduced blood loss with 72% fewer patients requiring a blood transfusion, 2.5 times fewer patients with a serious adverse event, nearly 50% fewer patients needing analgesics or narcotics for groin pain, and discharge from the hospital 0.5 days earlier.

Company comments

John McDermott, Chairman, President and Chief Executive Officer of Endologix, said, “We are pleased to receive FDA approval for our PEVAR indication, which provides our sales force with another unique AAA technology to offer our customers. We are now the first and only Company to receive a percutaneous indication for EVAR, which will allow us to begin training physicians on the PEVAR procedure using our unique platform of EVAR systems. We believe physicians and hospitals will be attracted to PEVAR because it is a less invasive procedure that has the potential to significantly reduce procedure times and improve the patient experience. We expect to begin PEVAR training courses in the second quarter, which will lead to a gradual increase in the number of percutaneous cases performed as we progress through the year.”

Source: Endologix, Inc.

Additional information here